Upstate Active Clinical Trials

Study Title:

S1914 - A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

What is the purpose of the study? (in Layman's terms, please describe the study)

This study is being done to answer the following question: can we extend your life by adding the immunotherapy drug atezolizumab to the usual radiation treatment?

Upstate Institutional Review Board (IRB) Number:

1723456

Study/Protocol ID:

S1914

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Michael D Mix, MD

Who is eligible?

You may be eligible to take part in this study if you have inoperable, early stage non-small cell lung cancer. Other inclusion criteria apply. Please contact the CRA for more information.

What is involved if I participate?

• How long is the study?
  5 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  Yes
• What tests and procedures are involved?
  Please contact the CRA for more information.

Where will the study take place?

Verona Cancer Center, Oswego Radiation Oncology and Medical Oncology, Hill Medical Center

Other Information:

Please contact the CRA for more information.

Who can I contact for more information?

Name: Erin Bingham, CCRP
Phone: 315-464-3603
Email: [email protected]

Return to Previous Page || Search Again